SCLX vs. OMGA, MOLN, VIGL, LIFE, BCAB, SGMO, CRDL, BLUE, DBVT, and VXRT
Should you be buying Scilex stock or one of its competitors? The main competitors of Scilex include Omega Therapeutics (OMGA), Molecular Partners (MOLN), Vigil Neuroscience (VIGL), aTyr Pharma (LIFE), BioAtla (BCAB), Sangamo Therapeutics (SGMO), Cardiol Therapeutics (CRDL), bluebird bio (BLUE), DBV Technologies (DBVT), and Vaxart (VXRT). These companies are all part of the "biological products, except diagnostic" industry.
Scilex (NASDAQ:SCLX) and Omega Therapeutics (NASDAQ:OMGA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.
Omega Therapeutics has lower revenue, but higher earnings than Scilex. Omega Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.
Scilex currently has a consensus target price of $6.00, suggesting a potential upside of 650.00%. Omega Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 323.73%. Given Scilex's higher probable upside, equities research analysts clearly believe Scilex is more favorable than Omega Therapeutics.
In the previous week, Omega Therapeutics had 7 more articles in the media than Scilex. MarketBeat recorded 18 mentions for Omega Therapeutics and 11 mentions for Scilex. Omega Therapeutics' average media sentiment score of 0.56 beat Scilex's score of 0.24 indicating that Omega Therapeutics is being referred to more favorably in the news media.
Omega Therapeutics received 19 more outperform votes than Scilex when rated by MarketBeat users. However, 100.00% of users gave Scilex an outperform vote while only 71.88% of users gave Omega Therapeutics an outperform vote.
Scilex has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Omega Therapeutics has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500.
Scilex has a net margin of -229.47% compared to Omega Therapeutics' net margin of -1,868.35%. Scilex's return on equity of 0.00% beat Omega Therapeutics' return on equity.
69.7% of Scilex shares are owned by institutional investors. Comparatively, 97.5% of Omega Therapeutics shares are owned by institutional investors. 8.7% of Scilex shares are owned by insiders. Comparatively, 57.0% of Omega Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Omega Therapeutics beats Scilex on 10 of the 17 factors compared between the two stocks.
Get Scilex News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
